
Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target
Processa Pharmaceuticals (PCSA) Analyst Ratings
Bulls say
Processa Pharmaceuticals Inc. has demonstrated a narrowing of its estimated net loss per share for full-year 2026 to $0.15, down from a prior estimate of $0.20, indicating improved financial efficiency despite an increased share count. The company is positioned for potential value enhancement due to promising interim data from the mid-stage trial of its lead product, NGC-Cap, which could serve as a significant inflection point for the stock. Furthermore, the recent securing of a strategic investment and the exploration of cryptocurrency treasury strategies highlight Processa's proactive approach to growth and financial stability, contributing to a favorable financial outlook.
Bears say
Processa Pharmaceuticals is projected to incur a full-year net loss of $0.43 per share in 2025, indicating ongoing financial challenges and insufficient profitability in the near future. The company faces risks associated with regulatory approvals, increased competition affecting pricing and market penetration, as well as potential issues relating to partnerships. Additionally, there exists a concern regarding possible dilution risk in the near to medium term, which could further impact the stock's attractiveness to investors.
This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Processa Pharmaceuticals (PCSA) Analyst Forecast & Price Prediction
Start investing in Processa Pharmaceuticals (PCSA)
Order type
Buy in
Order amount
Est. shares
0 shares